Skip to main content

Table 1 Baseline characteristics of the study population consisting of patients with familial adenomatous polyposis (FAP) and non-FAP patient controls

From: Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls

  Overall non-FAP group Overall FAP group p-value FAP group A: Celecoxib & UDCA FAP group B: Celecoxib & placebo p-value
Number of patients 16 37   19 18  
Age at study entry, median/range (yr) 53/23-67 42/22-67 0.092* 42/22-67 41/27-64 0.964*
Sex (n,%)    0.241†    0.618†
Male 5 (31) 18 (49)   10 (53) 8 (44)  
Female 11 (69) 19 (51)   9 (47) 10 (56)  
Body Mass Index, median/range (kg/m2) 26.1/19.4-44.2 25.6/18.8-34.5 0.779* 26.0/19.2-34.5 25.6/18.8-33.1 0.408*
Spigelman score at last surveillance before entry       0.985†
II   19 (51)‡   10 (53) 9 (50)‡  
III   17 (46)‡   9 (47) 8 (44)‡  
  1. *The p-value was calculated by the Mann–Whitney U test.
  2. †The p-value was calculated by the Chi-square test.
  3. ‡In 1 case data on Spigelman score at last surveillance gastroduodenoscopy before study entry was missing.
  4. Abbreviations: FAP, familial adenomatous polyposis; UDCA, ursodeoxycholic acid.